$MBRX
Moleculin Biotech, Inc.

2021 Q3 Form 10-Q Financial Statement

#000143774921019445 Filed on August 11, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.021M $2.434M $1.650M
YoY Change 21.75% 47.52% 11.49%
% of Gross Profit
Research & Development $4.095M $3.039M $3.329M
YoY Change -7.67% -8.71% 58.6%
% of Gross Profit
Depreciation & Amortization $41.00K $44.00K $52.00K
YoY Change -28.07% -15.38% 6.12%
% of Gross Profit
Operating Expenses $6.157M $5.517M $5.034M
YoY Change 0.1% 9.59% 38.6%
Operating Profit -$6.157M -$5.517M -$5.034M
YoY Change 0.1% 9.59% 38.6%
Interest Expense $1.765M $1.265M -$5.100M
YoY Change -35.82% -124.8% -311.62%
% of Operating Profit
Other Income/Expense, Net $13.00K $8.000K $17.00K
YoY Change 30.0% -52.94%
Pretax Income -$4.379M -$4.244M -$10.11M
YoY Change 28.98% -58.02% 728.69%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.379M -$4.244M -$10.11M
YoY Change 28.98% -58.03% 728.17%
Net Earnings / Revenue
Basic Earnings Per Share -$0.15 -$0.15
Diluted Earnings Per Share -$153.3K -$149.2K -$1.020M
COMMON SHARES
Basic Shares Outstanding 28.55M 28.45M 60.40M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $75.18M $79.51M $16.73M
YoY Change 487.33% 375.23% -10.53%
Cash & Equivalents $75.20M $79.50M $16.73M
Short-Term Investments
Other Short-Term Assets $1.892M $2.330M $436.0K
YoY Change 636.19% 434.4% -71.13%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $77.07M $81.84M $19.75M
YoY Change 405.38% 314.38% -2.24%
LONG-TERM ASSETS
Property, Plant & Equipment $353.0K $395.0K $238.0K
YoY Change -32.38% 65.97% -40.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $11.63M $11.70M $11.63M
YoY Change -2.2% 0.58% -0.18%
TOTAL ASSETS
Total Short-Term Assets $77.07M $81.84M $19.75M
Total Long-Term Assets $11.63M $11.70M $11.63M
Total Assets $88.70M $93.53M $31.38M
YoY Change 226.78% 198.07% -1.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.390M $1.505M $1.918M
YoY Change 3.5% -21.53% 52.59%
Accrued Expenses $2.266M $1.845M $1.821M
YoY Change 8.16% 1.32% 31.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.656M $3.350M $3.739M
YoY Change 6.34% -10.4% -61.02%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.787M $5.484M $12.01M
YoY Change -59.02% -54.34% 6964.71%
Total Long-Term Liabilities $3.787M $5.484M $12.01M
YoY Change -59.02% -54.34% 6964.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.656M $3.350M $3.739M
Total Long-Term Liabilities $3.787M $5.484M $12.01M
Total Liabilities $7.443M $8.834M $15.75M
YoY Change -41.29% -43.91% 61.35%
SHAREHOLDERS EQUITY
Retained Earnings -$70.00M -$65.60M -$50.90M
YoY Change 28.91% 28.88% 61.08%
Common Stock $151.2M $150.3M $66.49M
YoY Change 120.06% 126.0% 23.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $81.26M $84.70M $15.63M
YoY Change
Total Liabilities & Shareholders Equity $88.70M $93.53M $31.38M
YoY Change 226.78% 198.07% -1.49%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$4.379M -$4.244M -$10.11M
YoY Change 28.98% -58.03% 728.17%
Depreciation, Depletion And Amortization $41.00K $44.00K $52.00K
YoY Change -28.07% -15.38% 6.12%
Cash From Operating Activities -$4.288M -$6.785M -$4.940M
YoY Change -20.15% 37.35% -7.49%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$20.00K
YoY Change -100.0% -100.0% 100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 -$20.00K
YoY Change -100.0% -100.0% 100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -24.00K -2.000K 10.01M
YoY Change -101.36% -100.02% -34.49%
NET CHANGE
Cash From Operating Activities -4.288M -6.785M -4.940M
Cash From Investing Activities 0.000 0.000 -20.00K
Cash From Financing Activities -24.00K -2.000K 10.01M
Net Change In Cash -4.312M -6.787M 5.050M
YoY Change 9.44% -234.4% -49.14%
FREE CASH FLOW
Cash From Operating Activities -$4.288M -$6.785M -$4.940M
Capital Expenditures $0.00 $0.00 -$20.00K
Free Cash Flow -$4.288M -$6.785M -$4.920M
YoY Change -14.75% 37.91% -7.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28552213
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28552213
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
155000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
202000 USD
CY2021Q2 us-gaap Assets
Assets
93534000 USD
CY2020Q4 us-gaap Assets
Assets
29031000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1505000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1129000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1845000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1791000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3350000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2920000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
94000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
159000 USD
CY2021Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
5390000 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
8192000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
8834000 USD
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28552213
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11536720
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11536720
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
6159000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
403000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
709000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
336000 USD
CY2021Q2 mbrx Number Of Core Drug Technologies
NumberOfCoreDrugTechnologies
3 pure
CY2021Q2 mbrx Number Of Drug Candidates
NumberOfDrugCandidates
6 pure
CY2021Q2 mbrx Number Of Drugs In Clinical Trials
NumberOfDrugsInClinicalTrials
5 pure
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
0 USD
CY2020Q2 us-gaap Sublease Income
SubleaseIncome
10000 USD
us-gaap Sublease Income
SubleaseIncome
21000 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79506000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15173000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2330000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2025000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
81836000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
17198000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
395000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
483000 USD
CY2021Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 USD
CY2020Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
11271000 USD
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
29000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
69000 USD
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
150231000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
74671000 USD
CY2021Q2 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
10000 USD
CY2020Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
129000 USD
CY2021Q2 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
55000 USD
CY2020Q4 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
65000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65605000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56916000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
84700000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
17760000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
93534000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29031000 USD
CY2021Q2 us-gaap Revenues
Revenues
0 USD
CY2020Q2 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
18000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22000 USD
CY2021Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
92000 USD
CY2020Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
149000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
7000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4244000 USD
us-gaap Revenues
Revenues
0 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3039000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3329000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7145000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6535000 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2434000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1653000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4373000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3463000 USD
CY2021Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
44000 USD
CY2020Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
52000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
88000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
98000 USD
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
5517000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
5034000 USD
us-gaap Operating Expenses
OperatingExpenses
11606000 USD
us-gaap Operating Expenses
OperatingExpenses
10096000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5517000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5034000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-11606000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-10096000 USD
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1173000 USD
CY2020Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5099000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2750000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1254000 USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-10112000 USD
us-gaap Net Income Loss
NetIncomeLoss
-8689000 USD
us-gaap Net Income Loss
NetIncomeLoss
-11321000 USD
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.24
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28451532
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9913878
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25148399
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9117856
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4244000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-10112000 USD
us-gaap Net Income Loss
NetIncomeLoss
-8689000 USD
us-gaap Net Income Loss
NetIncomeLoss
-11321000 USD
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-6000 USD
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
25000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-10000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-8000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4250000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10087000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8699000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11329000 USD
us-gaap Net Income Loss
NetIncomeLoss
-8689000 USD
us-gaap Net Income Loss
NetIncomeLoss
-11321000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
88000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
98000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
838000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
805000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2750000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1254000 USD
mbrx Operating Lease Noncash Expense Net
OperatingLeaseNoncashExpenseNet
109000 USD
mbrx Operating Lease Noncash Expense Net
OperatingLeaseNoncashExpenseNet
95000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
305000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
266000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
376000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-235000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-72000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
295000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10405000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9275000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
63000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
74685000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15298000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
74748000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15303000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-10000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-9000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
64333000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5999000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15173000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10735000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79506000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16734000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
7000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
15000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
21000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
17760000 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
74684000 USD
CY2021Q1 mbrx Stockholders Equity Adjustments Reverse Stock Split
StockholdersEquityAdjustmentsReverseStockSplit
0 USD
CY2021Q1 mbrx Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
116000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
405000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4445000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-4000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
88516000 USD
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1000 USD
CY2021Q2 mbrx Subscription Of Common Stock Value
SubscriptionOfCommonStockValue
0 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
433000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4244000 USD
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-6000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
84700000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
15571000 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
566000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
397000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1209000 USD
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-33000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
15292000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10007000 USD
CY2020Q2 mbrx Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
9000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
408000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-10112000 USD
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
25000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
15629000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
426000 USD
CY2021Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
78000 USD
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><b>Use of Estimates -</b> The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors <em style="font: inherit;"> may </em>affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often <em style="font: inherit;"> may </em>yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process <em style="font: inherit;"> may </em>result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </p>
us-gaap Net Income Loss
NetIncomeLoss
-8700000 USD
us-gaap Net Income Loss
NetIncomeLoss
-11300000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10400000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9300000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65600000 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79500000 USD
CY2021Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
6563000 USD
CY2021Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1173000 USD
CY2021Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
5390000 USD
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
8192000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
52000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
2750000 USD
CY2021Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
5390000 USD
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
106000 USD
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4000000.0
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3500000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3900000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3300000
CY2021Q2 mbrx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1098000 USD
CY2020Q4 mbrx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
907000 USD
CY2021Q2 mbrx Accrued Legal Regulatory Professional And Other Current
AccruedLegalRegulatoryProfessionalAndOtherCurrent
437000 USD
CY2020Q4 mbrx Accrued Legal Regulatory Professional And Other Current
AccruedLegalRegulatoryProfessionalAndOtherCurrent
262000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1791000 USD
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
78000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1845000 USD
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
433000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
408000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
838000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
805000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
532865
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.24
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.75
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
us-gaap Operating Lease Cost
OperatingLeaseCost
58000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
58000 USD
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
7000 USD
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
7000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
14000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
14000 USD
CY2021Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0 USD
CY2020Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4000 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0 USD
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
29000 USD
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
29000 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
9000 USD
CY2021Q2 us-gaap Lease Cost
LeaseCost
36000 USD
CY2020Q2 us-gaap Lease Cost
LeaseCost
40000 USD
us-gaap Lease Cost
LeaseCost
72000 USD
us-gaap Lease Cost
LeaseCost
81000 USD
CY2021Q2 us-gaap Sublease Income
SubleaseIncome
10000 USD
us-gaap Sublease Income
SubleaseIncome
21000 USD
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
34000 USD
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
33000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
68000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
66000 USD
CY2021Q2 mbrx License Agreements Expense
LicenseAgreementsExpense
56000 USD
CY2020Q2 mbrx License Agreements Expense
LicenseAgreementsExpense
61000 USD
mbrx License Agreements Expense
LicenseAgreementsExpense
94000 USD
mbrx License Agreements Expense
LicenseAgreementsExpense
122000 USD

Files In Submission

Name View Source Status
0001437749-21-019445-index-headers.html Edgar Link pending
0001437749-21-019445-index.html Edgar Link pending
0001437749-21-019445.txt Edgar Link pending
0001437749-21-019445-xbrl.zip Edgar Link pending
ex_250349.htm Edgar Link pending
ex_250350.htm Edgar Link pending
ex_250351.htm Edgar Link pending
ex_250352.htm Edgar Link pending
ex_269494.htm Edgar Link pending
ex_269495.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mbrx-20210630.xsd Edgar Link pending
mbrx-20210630_cal.xml Edgar Link unprocessable
mbrx-20210630_def.xml Edgar Link unprocessable
mbrx-20210630_lab.xml Edgar Link unprocessable
mbrx-20210630_pre.xml Edgar Link unprocessable
mbrx20210630_10q.htm Edgar Link pending
mbrx20210630_10q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
moleculinlogoresizedclear.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending